Goldman Sachs’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-11,147
| Closed | -$7K | – | 6747 |
|
|
2017
Q4 | $7K | Sell |
11,147
-394
| -3% | -$199 | ﹤0.01% | 6234 |
|
|
2017
Q3 | $4K | Sell |
11,541
-1,566
| -12% | -$549 | ﹤0.01% | 6594 |
|
|
2017
Q2 | $6K | Sell |
13,107
-518
| -4% | -$376 | ﹤0.01% | 6692 |
|
|
2017
Q1 | $16K | Sell |
13,625
-4,520
| -25% | -$5.65K | ﹤0.01% | 6563 |
|
|
2016
Q4 | $24K | Buy |
18,145
+2,855
| +19% | +$4.96K | ﹤0.01% | 6606 |
|
|
2016
Q3 | $32K | Sell |
15,290
-328
| -2% | -$649 | ﹤0.01% | 6629 |
|
|
2016
Q2 | $25K | Sell |
15,618
-41,426
| -73% | -$79.5K | ﹤0.01% | 6653 |
|
|
2016
Q1 | $55K | Sell |
57,044
-114,387
| -67% | -$112K | ﹤0.01% | 6384 |
|
|
2015
Q4 | $207K | Sell |
171,431
-7,284
| -4% | -$23.4K | ﹤0.01% | 5678 |
|
|
2015
Q3 | $1.33M | Buy |
178,715
+55,939
| +46% | +$428K | ﹤0.01% | 4189 |
|
|
2015
Q2 | $878K | Buy |
122,776
+66,965
| +120% | +$522K | ﹤0.01% | 4656 |
|
|
2015
Q1 | $479K | Sell |
55,811
-106,414
| -66% | -$952K | ﹤0.01% | 5176 |
|
|
2014
Q4 | $1.62M | Buy |
162,225
+114,961
| +243% | +$980K | ﹤0.01% | 4073 |
|
|
2014
Q3 | $468K | Sell |
47,264
-4,495
| -9% | -$66.6K | ﹤0.01% | 5338 |
|
|
2014
Q2 | $895K | Sell |
51,759
-37,935
| -42% | -$618K | ﹤0.01% | 4790 |
|
|
2014
Q1 | $1.59M | Buy |
89,694
+26,574
| +42% | +$514K | ﹤0.01% | 4205 |
|
|
2013
Q4 | $1.16M | Buy |
63,120
+48,286
| +326% | +$912K | ﹤0.01% | 4605 |
|
|
2013
Q3 | $398K | Sell |
14,834
-212,779
| -93% | -$4.56M | ﹤0.01% | 5338 |
|
|
2013
Q2 | $4.2M | Buy |
+227,613
| New | +$4.02M | ﹤0.01% | 2923 |
|
Goldman Sachs's RPRX Position: Q1 2018 in Review
Goldman Sachs sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 11,147 shares — an estimated $7K sold.
Goldman Sachs first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $4.2M in Q2 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Goldman Sachs reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Goldman Sachs sold 11,147 Repros Therapeutics Inc. shares in Q1 2018, an estimated $7K.
- Goldman Sachs first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
- Goldman Sachs's Repros Therapeutics Inc. position peaked at $4.2M in Q2 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.